title: Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.
abstract: BACKGROUND
  Compared with growth factor (G) alone, the combination of G with plerixafor (G + P) increases peripheral blood CD34+ count (PB-CD34+) and improves CD34+ collection yield (yCD34+) in multiple myeloma and lymphoma patients undergoing autologous hematopoietic progenitor cell (AHPC) mobilization. It is unknown whether the improved yCD34+ with G + P results entirely from expansion of PB-CD34+ or also from increased intraapheresis CD34+ recruitment and collection efficiency.
  
  
  METHODS
  We retrospectively studied 192 patients who underwent AHPC mobilization and collection with G (n = 73) or G + P (n = 119) to compare the adjusted relative efficiency (aRE), the proportion of the circulating CD34+ pool that is captured for each blood volume processed. Additionally, in a prospective cohort of nine patients mobilizing with G and 11 with G + P, PB-CD34+ after leukapheresis allowed calculation of the recruitment coefficient (RC), proportion of the initial CD34+ pool recruited from the marrow into peripheral blood for each blood volume processed.
  
  
  RESULTS
  There was no difference in aRE between G and G + P (0.50 vs. 0.46; p = 0.37) and no substantial decline in aRE with higher blood volumes processed in either group. RC was also not different between G and G + P (median, 0.39 and 0.38, respectively; p = 0.7). Prediction of yCD34+ was determined essentially by PB-CD34+ and not affected independently by plerixafor.
  
  
  CONCLUSIONS
  Kinetics of intraapheresis CD34+ recruitment and collection is proportional to PB-CD34+ but not influenced further by plerixafor.
authors.affiliation: Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: Henning
authors.initials: H
authors.lastname: Schade
authors.forename: Saurabh
authors.initials: S
authors.lastname: Chhabra
authors.forename: Yubin
authors.initials: Y
authors.lastname: Kang
authors.forename: Robert K
authors.initials: RK
authors.lastname: Stuart
authors.forename: Kathy H
authors.initials: KH
authors.lastname: Edwards
authors.forename: Cindy
authors.initials: C
authors.lastname: Kramer
authors.forename: Coleen
authors.initials: C
authors.lastname: Butcher
authors.forename: Amanda
authors.initials: A
authors.lastname: Littleton
authors.forename: Molly
authors.initials: M
authors.lastname: Schneider
authors.forename: Milos N
authors.initials: MN
authors.lastname: Budisavljevic
authors.forename: Luciano J
authors.initials: LJ
authors.lastname: Costa
mesh_terms: D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D018952:Antigens, CD34; D064592:Autografts; D001596:Benzylamines; D001781:Blood Component Removal; D000080027:Cyclams; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells; D006571:Heterocyclic Compounds / Q000008:administration & dosage*; D006801:Humans; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D012189:Retrospective Studies
chemical_list: D019380:Anti-HIV Agents; D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; C088327:plerixafor